Article Details

NTAGI may soon review efficacy data of India's first intranasal Covid vaccine

Retrieved on: 2022-06-01 20:47:57

Tags for this article:

Click the tags to see associated articles and topics

NTAGI may soon review efficacy data of India's first intranasal Covid vaccine. View article details on hiswai:

Excerpt

... conduct standalone phase III trials on its Covid-19 intranasal vaccine. The company also received approval to evaluate the intranasal vaccine, ...

Article found on: economictimes.indiatimes.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up